Molecular Partners announces collaboration with Novartis to develop two DARPin therapies designed for potential use against COVID-19.
New evidence shows psoriasis can be treated with a microbe derived from gut bacteria.
Insmed’s Arikayce receives marketing authorization for treatment of mycobacterial lung infections
Enhertu granted priority review in the US for the treatment of HER2-positive metastatic gastric cancer.
Neovasc announces FDA Advisory Panel result on Neovasc Reducer medical device for the treatment of refractory angina.
Phase III GEMINI 1 and 2 clinical trials of AGN 190584 meet primary endpoints in presbyopia.
Novavax provides phase III NVX-CoV2373, COVID-19 vaccine clinical development update.
Global Coalition for Adaptive Research, Amgen, and Eisaiannounce first patient enrolled in REMAP-COVID trial involving apremilast and eritoran.
NIH-Sponsored ACTIV-3 trial closes LY-CoV555 sub-study.
Xarelto filed with FDA for a supplemental approval in peripheral artery disease.
Sobi and Apellis collaborate on the development and commercialisation of pegcetacoplan.
FDA grants 510(k) clearance for a cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System.
PF 04965842 filed with MAA and FDA for atopic dermatitis.
Spectrum Pharmaceuticals announces that the FDA is deferring its action on the BLA for Rolontis to treat neutropenia.
Dupixent late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented at ACG and UEG meetings- Sanofi.
Bayer acquires Asklepios BioPharmaceutical, Inc. (AskBio) a gene therapy company
Phase III DAPA-CKD trial of Farxiga shows efficacy in chronic kidney disease.- AstraZeneca
Phase III pivotal trial of M 001 vaccine fails to meet primary endpoints in influenza.- BiondVax Pharma
Phase III FIDELIO-DKD study of BAY 94 8862 shows benefits in chronic kidney disease + T2D.- Bayer
Phase III PRO2TECT study of Vafseo meets primary endpoints in anemia due to chronic kidney disease.- Akebia Therapeutics
Ultragenyx and Solid Biosciences announce strategic collaboration to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy
First patient dosed in phase III clinical trial of monalizumab + cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck,- Innate Pharma + AstraZeneca.
Farxiga DAPA-CKD Phase III trial reduced worsening of kidney function, risk of cardiovascular or renal death in patients with chronic kidney disease, irrespective of underlying cause.- AstraZeneca
FDA authorises restart of the COVID-19 AZD 1222 vaccine US phase III trial.- AstraZeneca
Pivotal trial of OMS 721 shows efficacy in HSCT-TMA.- Omeros Corp
Alnylam presents positive results from ILLUMINATE-B phase III study of lumasiran in pediatric patients with primary hyperoxaluria type 1 at the American Society of Nephrology Kidney Week.
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase IIb dose-ranging induction trial.-
InDEx Pharma and Merck KGaA
The importance of microbiome diversity
Over the horizon: early stage trials for NASH
Phase II trials and stem cell therapies
The next global epidemic
The latest treatments in NASH
The future of organ transplantation
Complications of stem cell transplants
Treating rejection in organ transplants
Challenges in transplant organ rejection
Biologic efficacy for complications associated with moderate-to-severe psoriasis
Moderate-to-severe psoriasis: treatment for young women
Migraine treatments: On the horizon
An independent review of current treatments for migraine
Migraine: The forgotten epidemic?
NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com
Senolytics: Can we treat age-related diseases with a single drug
Long-term disease control in Psoriasis: announcing a new project